Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?—Potential therapeutic applications
Pauline Roché(Hôpital de la Conception), Laure Farnault(Aix-Marseille Université), Raphaëlle Fanciullino(Inserm), Régis Costello(Inserm), Geoffroy Venton(Inserm), Julien Colle(Inserm), Hubert Lépidi(Centre National de la Recherche Scientifique), Shirley Fritz(Hôpital de la Conception), Vadim Ivanov(Hôpital de la Conception), Antoine Tichadou(Assistance Publique Hôpitaux de Marseille), Cédric Mercier(Inserm), Yaël Berda‐Haddad(Assistance Publique Hôpitaux de Marseille)
Cited by 4
Related Papers
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
Molecular Diagnosis of Infective Endocarditis by PCR Amplification and Direct Sequencing of DNA from Valve Tissue
|Journal of Clinical Microbiology|2003|184
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
|Blood Cancer Journal|2016|74
High incidence of atrial fibrillation in patients treated with ibrutinib
|Open Heart|2019|72